Studies have identified that inhibitors of the PTEN/Akt/GSK3β signaling cascade and regulation of β-catenin act as potential agents to effectively target cancer stem cells and tumorigenic cancer cells [3, 4]. This evidence concerns the gene GSK3B and cancer.